Ligand Pharmaceuticals (LGND) Gains from Sales and Divestitures (2012)
Ligand Pharmaceuticals' (LGND) quarterly Gains from Sales and Divestitures came in at $71406.0 in Q2 2012.
Ligand Pharmaceuticals (LGND) Gains from Sales and Divestitures (2012) Analysis & Trends
Ligand Pharmaceuticals has disclosed Gains from Sales and Divestitures across 1 years of filings, most recently posting $71406.0 for Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ligand Pharmaceuticals | 5.47 Bn | 4.69 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2012 | 71,406.00 |
| Jun 30, 2012 | 71,406.00 |